Swipe om te navigeren naar een ander artikel
The EORTC QLQ-PR25 was primarily developed to measure disease-specific health-related quality of life (HRQoL) of prostate cancer (PCa) patients undergoing active treatment. The growing number of cancer survivors has focussed interest on assessing survivors’ HRQoL. We evaluated psychometric properties of the EORTC QLQ-PR25 questionnaire amongst PCa survivors.
A postal questionnaire, including the QLQ-PR25, was administered to 6559 PCa survivors 2–18 years post-diagnosis, identified through population-based cancer registries in Ireland; 3348 participated. The QLQ-PR25 has been suggested to have five multi-item subscales measuring urinary (US), bowel (BS) and hormone treatment-related symptoms (TS), sexual activity (SA) and sexual functioning (SF), and a single item measuring bother due to using incontinence aids (IA). Reliability analysis, divergent validity, discriminant validity (compared to EORTC QLQ-C30, DASS-21 and EuroQoL EQ-5D-5L), and exploratory and confirmatory factor analysis (EFA, CFA) were undertaken.
The percentage of survivors completing QLQ-PR25 subscales was: US-79 %; IA-20 %; BS-83 %; TS-86 %; SA-87 %; and SF-26 %. Reliability was acceptable (Cronbach’s α > 0.7) for three subscales (US, SA, SF). The instrument discriminated well between clinically distinct groups, especially those defined by primary treatment(s) and stage at diagnosis. The SA and SF subscales showed good discriminant validity compared to QLQ-C30, DASS-21 and EQ-5D-5L; other subscales did not. EFA reproduced a near fit to the proposed factor structure. CFA confirmed this.
This is the largest ever QLQ-PR25 validation study. When used in PCa survivors, although the proposed factor structure was confirmed, some of the subscales (e.g. BS and TS) showed poor reliability, a lack of discriminant validity and moderate levels of item non-response.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
International Agency for Research on Cancer. GLOBOCAN, 2012. Fact sheets by cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 21 Aug 2014.
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241.
Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Thomas, A. A., Timmons, A., & Comber, H. (2014). The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care. BMC Cancer, 14(1), 767.
Bray, F., Ren, J.-S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132(5), 1133–1145. CrossRef
Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013). Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 16(2), 111–122. PubMed
Van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., et al. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418–2424. PubMedCrossRef
Chie, W.-C., Yu, C.-C., & Yu, H.-J. (2010). Reliability and validity of the Taiwan Chinese version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urological Science, 21(3), 118–125. CrossRef
Park, J., Shin, D. W., Yun, S. J., Park, S.-W., Jeon, S. S., Kwak, C., et al. (2013). Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with prostate cancer-EORTC QLQ-PR25. Oncology, 85(5), 299–305. PubMedCrossRef
Drummond, F.J., Kinnear, H., O’Leary, E., Donnelly, Gavin, A., & Sharp, L. (2015). Long-term health related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship: Research and Practice. doi: 10.1007/s11764-014-0419-6.
Selli, C., Bjartell, A., Burgos, J., Somerville, M., Palacios, J.-M., Benjamin, L., et al. (2014). Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-European observational study. Prostate Cancer, 2014, 1–8. CrossRef
Macmillan Cancer Support. Living with or beyond cancer. http://www.macmillan.org.uk/GetInvolved/Campaigns/Weareaforceforchange/Survivorship/Livingwithorbeyondcancer.aspx. Accessed 02 Feb 2015.
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. PubMedCrossRef
Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the depression anxiety stress scales (2nd ed.). Sydney: Psychology Foundation.
EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef
Oemar, M., & Janssen, B. (2013). EQ-5D-5L user guide. Rotterdam: EuroQoL Group.
Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill.
Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6(1), 1–55. CrossRef
Glaser, A. W., Fraser, L. K., Corner, J., Feltbower, R., Morris, E. J. A., Hartwell, G., et al. (2013). Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: A cross-sectional survey. BMJ Open, 3(4), E002317.
- Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg
Frances J. Drummond
- Springer International Publishing